Sodium Bicarbonate Injection · 3,481 days since initial FDA posting
FDA lists Sodium Bicarbonate Injection as Active Shortage (Hospira, Inc., a Pfizer Company).
Availability on file: Unavailable
Sodium Bicarbonate Injection: Active Shortage
Unavailable Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Sodium Bicarbonate Injection
- Manufacturer
- Hospira, Inc., a Pfizer Company
- Dosage Form
- Injection
- Presentation
- Sodium Bicarbonate, Injection, 5 mEq/10 mL (4.2%, 0.5 mEq/mL) Syringes (NDC 0409-5534-14)
- Package NDC
- 0409-5534-14
Status & Timeline
- Status
- Active Shortage
- Availability
- Unavailable
- First Reported
- Mar 1, 2017
- Last Updated
- Mar 13, 2026
- Therapeutic Category
- Endocrinology/Metabolism, Gastroenterology, Pediatric
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
Discontinuation of the manufacture of the drug
Nearby, Other Sodium Shortage Records
Sodium Bicarbonate Injection
Fresenius Kabi USA, LLC
Injection
Sodium Bicarbonate Injection
Fresenius Kabi USA, LLC
Injection
Sodium Bicarbonate Injection
Hospira, Inc., a Pfizer Company
Injection
Sodium Bicarbonate Injection
Hospira, Inc., a Pfizer Company
Injection
Sodium Bicarbonate Injection
Hospira, Inc., a Pfizer Company
Injection
Sodium Bicarbonate Injection
Hospira, Inc., a Pfizer Company
Injection
FDA reason on file: Discontinuation of the manufacture of the drug. General shortage guidance lives on the tracker hub.